News from Decision Resources, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 17, 2013, 09:28 ET Forty Blockbuster Drug Brands Will Lose Patent Exclusivity Between 2013 and 2020

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that between 2013...


Dec 16, 2013, 10:00 ET The Epilepsy Market Will Grow 2 Percent Annually Through 2022 with Expanding Uptake of Third-Generation Brands

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market...


Dec 16, 2013, 10:00 ET Unmet Need in Rare Cancers Remains High

   Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...


Dec 16, 2013, 09:00 ET U.S. Gastroenterologists Have Increased Their Use Of TNF-alpha Inhibitors For The Treatment Of Crohn's Disease Compared To Last Year

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through an...


Dec 16, 2013, 08:00 ET When Prescribing New Drugs for Crohn's Disease or Ulcerative Colitis, Surveyed EU5 Gastroenterologists Will Prioritize Remission Rates Over Cost and Reimbursement Hurdles

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when...


Dec 16, 2013, 08:00 ET Patient Share of Nexavar for Hepatocellular Carcinoma Will Double in China by 2016 if it Successfully Achieves Inclusion in Provincial Formularies

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that in China, the...


Dec 12, 2013, 12:00 ET The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the entry of...


Dec 12, 2013, 09:00 ET The Chinese Colorectal Cancer Market Will Grow Rapidly Over the Next Five Years, Increasing from Approximately $360 Million in 2012 to $575 Million in 2017

BURLINGTON, Mass., Dec. 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical...


Dec 12, 2013, 08:00 ET The Chronic Pain Drug Market Will Attain $21.6 Billion in Major-Market Sales by 2022

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain...


Dec 12, 2013, 08:00 ET South Korean Oncologists Are Significantly Less Familiar with Biosimilars than Their European Counterparts

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed South...


Dec 11, 2013, 10:00 ET The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of...


Dec 11, 2013, 08:00 ET Use of Roche's Herceptin Among HER2+ Gastric Cancer Patients May Double in China Over the Next Three Years

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that oncologists in...


Dec 11, 2013, 08:00 ET The Ovarian Cancer Drug Market is Set to More Than Double to $1.6 Billion by 2022

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that...


Dec 10, 2013, 11:00 ET The Combined Non-Small-Cell Lung Cancer Market of Argentina, Brazil and Mexico Will Grow at Six Percent Annually Through 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2013 to...


Dec 10, 2013, 10:15 ET High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the high cost...


Dec 10, 2013, 10:15 ET Opportunity Exists in the U.S. for Novel Agents in Crohn's Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that lack of initial...


Dec 10, 2013, 08:00 ET Approximately Two-Thirds of Surveyed Oncologists Believe that All Patients with NSCLC of Non-Squamous Histology Should be Tested for Molecular Characteristics

Decision Resources Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, in the...


Dec 09, 2013, 10:08 ET Analysis of U.S. Claims Data Shows a Slight Decline in First-Line Use of MAO-B Inhibitors for Parkinson's Disease Alongside Growing Use of Dopamine Agonists

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to...


Dec 09, 2013, 08:00 ET Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed...


Dec 09, 2013, 08:00 ET Value-Based Pricing is a Double-Edged Sword for Drug Manufacturers

 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that payers...